210 related articles for article (PubMed ID: 27160798)
21. MAP4K4 promotes pancreatic tumorigenesis via phosphorylation and activation of mixed lineage kinase 3.
Singh SK; Kumar S; Viswakarma N; Principe DR; Das S; Sondarva G; Nair RS; Srivastava P; Sinha SC; Grippo PJ; Thatcher GRJ; Rana B; Rana A
Oncogene; 2021 Oct; 40(43):6153-6165. PubMed ID: 34511598
[TBL] [Abstract][Full Text] [Related]
22. Expression and prognostic significance of MAP4K4 in lung adenocarcinoma.
Qiu MH; Qian YM; Zhao XL; Wang SM; Feng XJ; Chen XF; Zhang SH
Pathol Res Pract; 2012 Sep; 208(9):541-8. PubMed ID: 22824148
[TBL] [Abstract][Full Text] [Related]
23. A new function for MAP4K4 inhibitors during platelet aggregation and platelet-mediated clot retraction.
Nam GS; Kim S; Kwon YS; Kim MK; Nam KS
Biochem Pharmacol; 2021 Jun; 188():114519. PubMed ID: 33737052
[TBL] [Abstract][Full Text] [Related]
24. Identification of hypo- and hypermethylated genes related to atherosclerosis by a genome-wide analysis of DNA methylation.
Yamada Y; Nishida T; Horibe H; Oguri M; Kato K; Sawabe M
Int J Mol Med; 2014 May; 33(5):1355-63. PubMed ID: 24626634
[TBL] [Abstract][Full Text] [Related]
25. MAP4K4 exacerbates cardiac microvascular injury in diabetes by facilitating S-nitrosylation modification of Drp1.
Chen Y; Li S; Guan B; Yan X; Huang C; Du Y; Yang F; Zhang N; Li Y; Lu J; Wang J; Zhang J; Chen Z; Chen C; Kong X
Cardiovasc Diabetol; 2024 May; 23(1):164. PubMed ID: 38724987
[TBL] [Abstract][Full Text] [Related]
26. Deletion of Nck1 attenuates hepatic ER stress signaling and improves glucose tolerance and insulin signaling in liver of obese mice.
Latreille M; Laberge MK; Bourret G; Yamani L; Larose L
Am J Physiol Endocrinol Metab; 2011 Mar; 300(3):E423-34. PubMed ID: 20587749
[TBL] [Abstract][Full Text] [Related]
27. MAP4K4 promotes epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma.
Feng XJ; Pan Q; Wang SM; Pan YC; Wang Q; Zhang HH; Zhu MH; Zhang SH
Tumour Biol; 2016 Aug; 37(8):11457-67. PubMed ID: 27010469
[TBL] [Abstract][Full Text] [Related]
28. Role of Mitogen-activated protein kinase kinase kinase kinase 4 signaling in liver and metabolic diseases.
Ampadu F; Awasthi V; Joshi AD
J Pharmacol Exp Ther; 2024 Jun; ():. PubMed ID: 38844365
[TBL] [Abstract][Full Text] [Related]
29. Modulation of insulin action.
Pirola L; Johnston AM; Van Obberghen E
Diabetologia; 2004 Feb; 47(2):170-84. PubMed ID: 14722654
[TBL] [Abstract][Full Text] [Related]
30. Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma.
Liang JJ; Wang H; Rashid A; Tan TH; Hwang RF; Hamilton SR; Abbruzzese JL; Evans DB; Wang H
Clin Cancer Res; 2008 Nov; 14(21):7043-9. PubMed ID: 18981001
[TBL] [Abstract][Full Text] [Related]
31. Genetic Disruption of Protein Kinase STK25 Ameliorates Metabolic Defects in a Diet-Induced Type 2 Diabetes Model.
Amrutkar M; Cansby E; Chursa U; Nuñez-Durán E; Chanclón B; Ståhlman M; Fridén V; Mannerås-Holm L; Wickman A; Smith U; Bäckhed F; Borén J; Howell BW; Mahlapuu M
Diabetes; 2015 Aug; 64(8):2791-804. PubMed ID: 25845663
[TBL] [Abstract][Full Text] [Related]
32. Abrogation of MAP4K4 protein function causes congenital anomalies in humans and zebrafish.
Patterson V; Ullah F; Bryant L; Griffin JN; Sidhu A; Saliganan S; Blaile M; Saenz MS; Smith R; Ellingwood S; Grange DK; Hu X; Mireguli M; Luo Y; Shen Y; Mulhern M; Zackai E; Ritter A; Izumi K; Hoefele J; Wagner M; Riedhammer KM; Seitz B; Robin NH; Goodloe D; Mignot C; Keren B; Cox H; Jarvis J; Hempel M; Gibson CF; Tran Mau-Them F; Vitobello A; Bruel AL; Sorlin A; Mehta S; Raymond FL; Gilmore K; Powell BC; Weck K; Li C; Vulto-van Silfhout AT; Giacomini T; Mancardi MM; Accogli A; Salpietro V; Zara F; Vora NL; Davis EE; Burdine R; Bhoj E
Sci Adv; 2023 Apr; 9(17):eade0631. PubMed ID: 37126546
[TBL] [Abstract][Full Text] [Related]
33. Three mitogen-activated protein kinases inhibit insulin signaling by different mechanisms in 3T3-L1 adipocytes.
Fujishiro M; Gotoh Y; Katagiri H; Sakoda H; Ogihara T; Anai M; Onishi Y; Ono H; Abe M; Shojima N; Fukushima Y; Kikuchi M; Oka Y; Asano T
Mol Endocrinol; 2003 Mar; 17(3):487-97. PubMed ID: 12554784
[TBL] [Abstract][Full Text] [Related]
34. Overcoming radioresistance of breast cancer cells with MAP4K4 inhibitors.
Kwon YS; Lee MG; Kim NY; Nam GS; Nam KS; Jang H; Kim S
Sci Rep; 2024 Mar; 14(1):7410. PubMed ID: 38548749
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in the protein kinase B signaling pathway.
Woodgett JR
Curr Opin Cell Biol; 2005 Apr; 17(2):150-7. PubMed ID: 15780591
[TBL] [Abstract][Full Text] [Related]
36. Disruption of the SH2-B gene causes age-dependent insulin resistance and glucose intolerance.
Duan C; Yang H; White MF; Rui L
Mol Cell Biol; 2004 Sep; 24(17):7435-43. PubMed ID: 15314154
[TBL] [Abstract][Full Text] [Related]
37. MAP4K4 deletion inhibits proliferation and activation of CD4(+) T cell and promotes T regulatory cell generation in vitro.
Huang H; Tang Q; Chu H; Jiang J; Zhang H; Hao W; Wei X
Cell Immunol; 2014; 289(1-2):15-20. PubMed ID: 24681727
[TBL] [Abstract][Full Text] [Related]
38. Insulin signal transduction in normal cells and its role in carcinogenesis.
Müssig K; Häring HU
Exp Clin Endocrinol Diabetes; 2010 Jun; 118(6):356-9. PubMed ID: 20140848
[TBL] [Abstract][Full Text] [Related]
39. KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals.
Moleirinho S; Chang N; Sims AH; Tilston-Lünel AM; Angus L; Steele A; Boswell V; Barnett SC; Ormandy C; Faratian D; Gunn-Moore FJ; Reynolds PA
Oncogene; 2013 Apr; 32(14):1821-30. PubMed ID: 22614006
[TBL] [Abstract][Full Text] [Related]
40. Tribbles-1: a novel regulator of hepatic lipid metabolism in humans.
Bauer RC; Yenilmez BO; Rader DJ
Biochem Soc Trans; 2015 Oct; 43(5):1079-84. PubMed ID: 26517927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
